ライフサイエンスコーパス: allogeneic transplantation

1 tologous transplantation, and seven received allogeneic transplantation).

2 o exert veto functions and show evidence for allogeneic transplantation.

3 ates antitumor effects following MHC-matched allogeneic transplantation.

4 erving graft-versus-lymphoma activity during allogeneic transplantation.

5 ceive similar conditioning regimens prior to allogeneic transplantation.

6 l immunity induces vascular accommodation in allogeneic transplantation.

7 ft-versus-tumour effect of reduced-intensity allogeneic transplantation.

8 tment and/or NK-mediated rejection following allogeneic transplantation.

9 ed as an alternative to bone marrow (BM) for allogeneic transplantation.

10 is novel agent is worthy of further study in allogeneic transplantation.

11 l for reconstitution of viral immunity after allogeneic transplantation.

12 h as alemtuzumab, systemic chemotherapy, and allogeneic transplantation.

13 cells when used in preparative regimens for allogeneic transplantation.

14 preventing lung cellular infiltration after allogeneic transplantation.

15 omes of patients treated with autologous and allogeneic transplantation.

16 d with clinical outcomes after myeloablative allogeneic transplantation.

17 )-mobilized donors are increasingly used for allogeneic transplantation.

18 le fashion paralleling that for syngeneic or allogeneic transplantation.

19 obilize a high yield of progenitor cells for allogeneic transplantation.

20 spectively compared bone marrow and PBSC for allogeneic transplantation.

21 as a source of hematopoietic stem cells for allogeneic transplantation.

22 years from ASCT should be considered for an allogeneic transplantation.

23 ucing tolerance in mice and monkey models of allogeneic transplantation.

24 ation of the role of conditioning therapy in allogeneic transplantation.

25 ne responses in a non-human primate model of allogeneic transplantation.

26 The only curative therapy is allogeneic transplantation.

27 8 effector subset elicited in vivo following allogeneic transplantation.

28 lantation, and with increasing frequency for allogeneic transplantation.

29 successful strategies to use these cells for allogeneic transplantation.

30 lR, outcome was similar after autologous and allogeneic transplantation.

31 prophylaxis to reduce early mortality after allogeneic transplantation.

32 (GVHD) remains a significant complication of allogeneic transplantation.

33 a potential approach to immune modulation in allogeneic transplantation.

34 ents that may result in lower morbidity than allogeneic transplantation.

35 HHV-6 DNAemia was not so frequent after allogeneic transplantation.

36 ated, all exhibited WT1-CTL responses before allogeneic transplantation.

37 f hematopoietic stem cells (HSCs) for use in allogeneic transplantation.

38 e donor to proceed to a potentially curative allogeneic transplantation.

39 t/ABL1 was most prognostic for relapse after allogeneic transplantation.

40 ffectively with immunosuppressive therapy or allogeneic transplantation.

41 n of renal arteries after ischemia and after allogeneic transplantation.

42 tment and prevention of AML recurrence after allogeneic transplantation.

43 nonrelapse mortality after reduced intensity allogeneic transplantation.

44 dentify subjects most likely to benefit from allogeneic transplantation.

45 a promising novel immunomodulatory agent in allogeneic transplantation.

46 omorbidities should be considered for second allogeneic transplantation.

47 Encouraging results are reported after allogeneic transplantation.

48 d reduced-intensity conditioning followed by allogeneic transplantation.

49 versus-host disease (GVHD) prophylaxis after allogeneic transplantation.

50 Allogeneic transplantation (10-year probability, 7% vs 3

51 highly educated patients more often received allogeneic transplantation (16.3% v 8.7%).

52 chimerism could be detected without a prior allogeneic transplantation, (2) the toxicity of primary

53 ide as initial therapy for AML relapse after allogeneic transplantation achieved durable CR after dev

54 A second allogeneic transplantation after a prior allogeneic (all

55 nologically normal BALB/c mice that delaying allogeneic transplantation after TBI is a simple and eff

56 y Hodgkin lymphoma, but its impact on future allogeneic transplantation (allo-HCT) is not known.

57 nts with hematologic malignancies undergoing allogeneic transplantation (alloSCT), but its prognostic

58 widely adopted as a source of stem cells for allogeneic transplantation, although controversy remains

59 on-free survival, and overall survival after allogeneic transplantation and conditioning with fludara

60 eripheral blood progenitor cells (PBPCs) for allogeneic transplantation and granulocytes for transfus

61 ion of peripheral blood progenitor cells for allogeneic transplantation and granulocytes for transfus

62 Nonmyeloablative allogeneic transplantation and high-dose radioimmunother

63 tions in patients as early as 3 months after allogeneic transplantation and may be an effective strat

64 s costly, particularly if it follows a prior allogeneic transplantation, and is driven by the costs o

65 is of comparable intensity to that used for allogeneic transplantation, and offers an alternative ap

66 We compared treatment intensity, allogeneic transplantation, and response rates by educat

67 ve dose intensity, conditioning regimens for allogeneic transplantation are designed to immunosuppres

68 ersus-host disease following blood or marrow allogeneic transplantation are not yet available.

69 ave supplanted bone marrow in autologous and allogeneic transplantation as a source of hematopoietic

70 econd remission (CR2) and then proceeding to allogeneic transplantation as the definitive curative ap

71 rafts devoid of immunologic complications of allogeneic transplantation, as well as generating nonhem

72 em autologous/reduced intensity conditioning allogeneic transplantation (auto/RICallo) to autologous

73 nsplantation is an attractive alternative to allogeneic transplantation because of the intractable sh

74 molecules that have the potential to enhance allogeneic transplantation, boost blood cell production,

75 ated that the 4-day rest between the TBI and allogeneic transplantation broke the interaction of cell

76 lymphocytes could greatly expand the role of allogeneic transplantation by reducing graft-versus-host

77 d, however, before the curative potential of allogeneic transplantation can be assessed.

78 Allogeneic transplantation can cure a number of hematolo

79 Allogeneic transplantation combined with immunosuppressi

80 important component of the cure mediated by allogeneic transplantation comes from a graft-versus-tum

81 CR) had a significantly better outcome after allogeneic transplantation compared with other consolida

82 d to add between $15,300 and $28,100 each to allogeneic transplantation costs.

83 Although allogeneic transplantation cures a small proportion of p

84 s the source of hematopoietic stem cells for allogeneic transplantation, currently the only curative

85 Early T-cell reconstitution following allogeneic transplantation depends on the persistence an

86 tion for patients who are not candidates for allogeneic transplantation due to the lack of an appropr

87 Allogeneic transplantation during remission offers the b

88 y establish the role of blood stem cells for allogeneic transplantation, especially in patients with

89 Differences in the antibody response to allogeneic transplantation exist between groups defined

90 nocompetent murine model of minor mismatched allogeneic transplantation followed by donor-derived CD1

91 tients who had undergone a reduced intensity allogeneic transplantation for acute myeloid leukemia we

92 set up to prospectively evaluate the role of allogeneic transplantation for adults with acute lymphob

93 d FK506 can reduce the early mortality after allogeneic transplantation for advanced leukemia.

94 mission consolidation with cytarabine before allogeneic transplantation for AML in first CR is not as

95 haploidentical alphabeta+CD3+/CD19+-depleted allogeneic transplantation for children with nonmalignan

96 ansplant, is an important adverse outcome in allogeneic transplantation for CML.

97 improving the outcome of patients undergoing allogeneic transplantation for high-risk B-cell malignan

98 The best conditioning regimen before allogeneic transplantation for high-risk diffuse large B

99 In conclusion, results of allogeneic transplantation for HS are encouraging, with

100 mortality was higher than 30%, such as with allogeneic transplantation for intermediate or advanced

101 All patients had undergone allogeneic transplantation for malignant or nonmalignant

102 KIR-ligand mismatch may improve outcomes in allogeneic transplantation for MM.

103 ively safe option compared with conventional allogeneic transplantation for patients who have failed

104 Case reports suggest that allogeneic transplantation for patients with HIV and hem

105 Allogeneic transplantation for patients with lymphoma wh

106 ance status, there are curative options with allogeneic transplantation for selected patients.

107 Matched related allogeneic transplantations for ALL in first complete re

108 arative regimen is an important component of allogeneic transplantations for myelodysplasia (MDS) or

109 e report the outcomes of patients undergoing allogeneic transplantations for myeloma and reported to

110 s that PBSCs are better than bone marrow for allogeneic transplantation from HLA-identical siblings i

111 ents heterozygous for FVLeiden who underwent allogeneic transplantation from homozygous FV wild-type

112 In the mouse model of corneal allogeneic transplantation, galectin-8-induced lymphangi

113 The role of allogeneic transplantation has also been redefined in li

114 y of graft-versus-host disease (GVHD) during allogeneic transplantation has recently been reported; h

115 Both autologous and allogeneic transplantation have been used to treat and c

116 For allogeneic transplantation, host rats received injection

117 e been identified in human skin cancer after allogeneic transplantation; however, the donor contribut

118 ction and, if in remission, were assigned to allogeneic transplantation if they had a compatible sibl

119 vanced phase CML would predict relapse after allogeneic transplantation in 176 independent CP CML cas

120 phalan and a purine analog was evaluated for allogeneic transplantation in 86 patients who had a vari

121 1(+) MLL-rearranged AML seem to benefit from allogeneic transplantation in first CR.

122 re treated differently, with some undergoing allogeneic transplantation in first remission.

123 lity that T cell-mediated immune sequelae of allogeneic transplantation in humans may differ when don

124 TNF alone can substitute for allogeneic transplantation in inducing HCMV and MCMV ie

125 ult in toxicity when administered late after allogeneic transplantation in murine models of GVHD.

126 afts has been shown to ameliorate GVHD after allogeneic transplantation in murine models.

127 the safety and efficacy of nonmyeloablative allogeneic transplantation in patients with HIV infectio

128 zed nonrelapse-related mortality rates after allogeneic transplantation in patients with Hodgkin's ly

129 loablative conditioning regimen (MAC) before allogeneic transplantation in patients with myelodysplas

130 apted trials that evaluate reduced-intensity allogeneic transplantation in patients with predicted po

131 pite high treatment-related mortality rates, allogeneic transplantation in relapsed aggressive lympho

132 poietic stem cells for patients that require allogeneic transplantation in the absence of readily ava

133 These results suggest that nonmyeloablative allogeneic transplantation in the context of highly acti

134 den the eligibility for potentially curative allogeneic transplantation in various disease categories

135 expanded the potential cellular sources for allogeneic transplantation, including matched unrelated

136 nsplantation, concurrent viral infection and allogeneic transplantation increased epithelial injury a

137 Our data suggest that nonablative allogeneic transplantation is a safe and potentially eff

138 Determination of the optimal dose of TBI for allogeneic transplantation is complex and depends on sev

139 T-cell depletion of bone marrow for allogeneic transplantation is known to increase the risk

140 the regulation of the immune response after allogeneic transplantation is still poorly understood.

141 Allogeneic transplantation is typically limited to young

142 chronic myeloid leukemia (CML) on subsequent allogeneic transplantation is uncertain.

143 ngiogenesis occurred as early as day+2 after allogeneic transplantation mainly in GVHD typical target

144 (EGFP+) FCs persist for one month following allogeneic transplantation, making cold target inhibitio

145 Allogeneic transplantation may also be beneficial to a s

146 or (KIR) ligand-mismatched, T cell-depleted, allogeneic transplantation may have a reduced risk of re

147 Use of allogeneic transplantation may result in cure as well, b

148 osis factor (TNF)-alpha, which is induced by allogeneic transplantation, may have a role in reactivat

149 For allogeneic transplantation, mobilized blood cell collect

150 cells, as a model of cord blood in a murine allogeneic transplantation model (C57BL/6 [H-2(b)] --> B

151 e effects of this peptide were studied in an allogeneic transplantation model involving vascularized

152 ukin (IL)-10 has proven effective in various allogeneic transplantation models and for preventing rec

153 After allogeneic transplantation, murine stem cells (SCs) for

154 nd then used for islet autologous (n=21) and allogeneic transplantation (n=10).

155 Nonmyeloablative allogeneic transplantation (NMAT) infrequently cures act

156 ive, organ, joint, and tissue function after allogeneic transplantation of children with mucopolysacc

157 Allogeneic transplantation of foreign organs or tissues

158 tient was effectively cured of HIV following allogeneic transplantation of hematopoietic stem cells (

159 Allogeneic transplantation of hERG1-expressing cells int

160 Allogeneic transplantation of islets of Langerhans was f

161 n of ie gene expression in a murine model of allogeneic transplantation of kidneys latently infected

162 strate in mice that both congenic as well as allogeneic transplantation of low numbers of highly puri

163 Allogeneic transplantation of radiation chimeras previou

164 For selected patients, both autologous and allogeneic transplantation offer the possibility of prol

165 term effects of low-dose irradiation used in allogeneic transplantation on stem cells is less well kn

166 ransplantation (HDM/ASCT) followed by either allogeneic transplantation or bortezomib/lenalidomide ma

167 New advances in allogeneic transplantation, particularly reduced-intensi

168 n 65,000 transplant recipients, about 40% of allogeneic transplantations performed since 1964, and ab

169 lied a well-tolerated, nonirradiation-based, allogeneic transplantation protocol using nonmyeloablati

170 range, $28,200 to $148,200) and $105,300 for allogeneic transplantation (range, $32,500 to $338,000).

171 their induction and mechanism of function in allogeneic transplantation remain elusive.

172 dity and mortality rates, particularly after allogeneic transplantation, remain challenges that must

173 The relative merit of autologous versus allogeneic transplantation remains to be better defined.

174 mportant for the mediation and regulation of allogeneic transplantation responses.

175 Although allogeneic transplantation results in a lower risk of di

176 Though allogeneic transplantation results in long-term survival

177 pe CD4(+)NKT cells in suppressing GVHD in an allogeneic transplantation setting, demonstrating clinic

178 In the allogeneic transplantation setting, the one log more T c

179 aft-versus-leukemia effect, as occurs in the allogeneic transplantation setting.

180 e autologous and to approximately 75% in the allogeneic transplantation setting.

181 Nonmyeloablative allogeneic transplantation should be considered in high-

182 Allogeneic transplantation should only be performed in t

183 Rituximab treatment after allogeneic transplantation significantly reduced B-cell

184 Similarly in an allogeneic transplantation study (n = 335), diabetes was

185 In allogeneic transplantation, such adverse reactions can o

186 It is now well known that the outcome after allogeneic transplantation, such as incidence of acute r

187 gnificantly lower rate of chronic GVHD after allogeneic transplantation than the rate without ATG.

188 er, in mouse models of atheroma formation or allogeneic transplantation, the serological neutralizati

189 With regard to allogeneic transplantation, there is a growing realisati

190 mens, which have expanded the application of allogeneic transplantation to a growing number of hemato

191 m follow-up of prospective studies comparing allogeneic transplantation to autologous transplantation

192 y of hematopoiesis, suggesting strategies in allogeneic transplantation to avoid the adverse effects

193 Exploring the potential of allogeneic transplantation to eradicate disease has ther

194 ce the antitumor effect, and, in the case of allogeneic transplantation, to reduce toxicity.

195 capsule before transplantation, could induce allogeneic transplantation tolerance across two-haplotyp

196 D) is the primary nonrelapse complication of allogeneic transplantation, understanding of its pathoge

197 s to decreasing the occurrence of GVHD after allogeneic transplantation use T-cell depletion, use imm

198 This study shows that allogeneic transplantation using CD34+ selected PBSC res

199 The curative potential of allogeneic transplantation using conventional myeloablat

200 reat patients whose conditions relapse after allogeneic transplantation using donor leukocyte infusio

201 stitution is abrogated in both syngeneic and allogeneic transplantation using Treg-depleted mice as r

202 e biologic activity of donor immune cells in allogeneic transplantation varied between graft sources.

203 To clarify the indications for allogeneic transplantation vis-a-vis autologous transpla

204 Allogeneic transplantation was allowed.

205 Allogeneic transplantation was associated with a signifi

206 alues after completion of treatment or after allogeneic transplantation was studied by using cause-sp

207 As T cells are activated in allogeneic transplantation, we determined the role of IL

208 relapse rates were observed when results of allogeneic transplantation were compared with syngeneic

209 Allogeneic transplantation with CD6 depleted bone marrow

210 Allogeneic transplantation with haemopoietic stem cells

211 first patient cured of HIV-1 infection after allogeneic transplantation with nonfunctional CCR5 corec

212 Reduction in the toxicity of allogeneic transplantation with nonmyeloablative inducti

213 The role of allogeneic transplantation with reduced-intensity condit

214 To review the outcomes of allogeneic transplantation with regimens of varying tota

215 We examined whether mixed allogeneic transplantation with syngeneic plus allogenei

216 uld potentially reduce disease relapse after allogeneic transplantation without increasing toxicity,

217 CML became the most frequent indication for allogeneic transplantation worldwide.